Minimum Effective Local Anesthetic Volume for Ultrasound Guided Superior Trunk Block
Launched by CHINESE UNIVERSITY OF HONG KONG · Jun 23, 2021
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how much of a local anesthetic called levobupivacaine is needed to effectively numb the shoulder area for patients undergoing a specific type of shoulder surgery called arthroscopic rotator cuff repair. The goal is to find the smallest amount that can still provide good pain relief for at least 90% of the patients. The study is currently recruiting participants, and it welcomes individuals between the ages of 65 and 74 who are in good health (American Society of Anesthesiologists physical status I-III) and scheduled for this surgery.
To participate, patients should not be pregnant, have any skin infections at the injection site, or a history of allergies to local anesthetics. They also should not have any bleeding disorders or pre-existing nerve or muscle diseases. If eligible, participants can expect to receive the local anesthetic through an ultrasound-guided procedure, which helps ensure the medication is delivered precisely where it's needed to maximize pain relief during their surgery. This study aims to improve pain management during these surgeries, making recovery easier for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • American Society of Anesthesiologists (ASA) physical status I-III scheduled to undergo elective upper shoulder arthroscopic rotator cuff repair procedure
- Exclusion Criteria:
- • Patient refusal
- • pregnancy
- • skin infection at the site of block placement
- • history of allergy to local anaesthetic drugs
- • bleeding tendency or with evidence of coagulopathy
- • pre-existing neurological deficit or neuromuscular disease.
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shatin, New Territories, Hong Kong
Patients applied
Trial Officials
Manoj K Karmakar, MD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials